Thursday, June 16th, 2016

Complete report in Detailed at



Relapsed Chronic Lymphocytic Leukemia (CLL)


Wiseguyreports.Com Adds “Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Pipeline Professional Survey Review H1 2016” To Its Research Database.

The report provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 Sample Page of the Report @

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL) 
- The report reviews pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Relapsed Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects 
- The report assesses Relapsed Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL) 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Purchase a Single Licensed Copy @


Table of Content

Table of Contents 2 
List of Tables 5 
List of Figures 6 
Introduction 7 
Global Markets Direct Report Coverage 7 
Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 8 
Therapeutics Development 9 
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 9 
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10 
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11 
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13 
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14 
Late Stage Products 14 
Clinical Stage Products 15 
Early Stage Products 16 
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17 
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20 
Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21 
4SC AG 21 
AbbVie Inc. 22 
Astellas Pharma Inc. 23 
Astex Pharmaceuticals, Inc. 24 
AstraZeneca Plc 25 
Boehringer Ingelheim GmbH 26 
Bristol-Myers Squibb Company 27 
Celgene Corporation 28 
Cyclacel Pharmaceuticals, Inc. 29 
Emergent BioSolutions Inc. 30 
F. Hoffmann-La Roche Ltd. 31 
Hutchison MediPharma Limited 32 
ImmunoGen, Inc. 33 
Immunomedics, Inc. 34 
Incyte Corporation 35 
Infinity Pharmaceuticals, Inc. 36 
Innate Pharma S.A. 37 
Juno Therapeutics Inc. 38 
Karyopharm Therapeutics, Inc. 39 
Les Laboratoires Servier SAS 40 
LFB S.A. 41 
Lymphocyte Activation Technologies, S.A. 42 
Millennium Pharmaceuticals, Inc. 43 
MorphoSys AG 44 
Novartis AG 45 
Oncternal Therapeutics, Inc. 46 
Ono Pharmaceutical Co., Ltd. 47 
Portola Pharmaceuticals, Inc. 48 
Sanofi 49      



Contact US:                   


Partner Relations & Marketing Manager

[email protected]   

Ph: +1-646-845-9349 (US)      

Ph: +44 208 133 9349 (UK)



Contact Profile


Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

Our Market Research Reports and Consulting Services 

Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. The Wise Guy Reports team prides itself in being the chosen source for market research reports, report customizations services, and other ancillary services such as a Newsletter service and corporate service for large organizations.

Hundreds of large and small organizations across virtually every industry sector worldwide are currently reaping rich dividends from the sharp insights provided by market research reports sourced through Wise Guy Reports. 

Gaining an insight into emerging trends, opportunities and potential threats is key to long-term sustenance in a competitive environment. The handpicked collection of market research reports on Wise Guy Reports is centred on this proven principle.

Norah Trent
P: +44 208 133 9349
M: +1 646 845 9349


Relapsed Chronic Lymphocytic Leukemia (CLL) ,Relapsed Chronic Lymphocytic Leukemia (CLL) Industry ,Relapsed Chronic Lymphocytic Leukemia (CLL) Market ,Relapsed Chronic Lymphocytic Leukemia (CLL) Market Trends, Relapsed Chronic Lymphocytic Leukemia (CLL)




More Formats

View QR Code